CY1119674T1 - Θεραπεια και προληψη της νοσου αλτσχαϊμερ (ad) - Google Patents
Θεραπεια και προληψη της νοσου αλτσχαϊμερ (ad)Info
- Publication number
- CY1119674T1 CY1119674T1 CY20171101303T CY171101303T CY1119674T1 CY 1119674 T1 CY1119674 T1 CY 1119674T1 CY 20171101303 T CY20171101303 T CY 20171101303T CY 171101303 T CY171101303 T CY 171101303T CY 1119674 T1 CY1119674 T1 CY 1119674T1
- Authority
- CY
- Cyprus
- Prior art keywords
- prevention
- alzheimer
- disease treatment
- treatment
- disease
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166355 | 2014-04-29 | ||
| EP14166354 | 2014-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119674T1 true CY1119674T1 (el) | 2018-04-04 |
Family
ID=53039896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101303T CY1119674T1 (el) | 2014-04-29 | 2017-12-13 | Θεραπεια και προληψη της νοσου αλτσχαϊμερ (ad) |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10478454B2 (enExample) |
| EP (2) | EP3269376B1 (enExample) |
| JP (1) | JP6692755B2 (enExample) |
| KR (1) | KR102388363B1 (enExample) |
| CN (1) | CN106659738B (enExample) |
| AU (1) | AU2015254663B2 (enExample) |
| CA (1) | CA2946928C (enExample) |
| CY (1) | CY1119674T1 (enExample) |
| DK (1) | DK3137093T3 (enExample) |
| ES (2) | ES2824763T3 (enExample) |
| HR (1) | HRP20171896T1 (enExample) |
| HU (1) | HUE037501T2 (enExample) |
| LT (1) | LT3137093T (enExample) |
| NO (1) | NO3137093T3 (enExample) |
| PL (1) | PL3137093T3 (enExample) |
| PT (1) | PT3137093T (enExample) |
| SI (1) | SI3137093T1 (enExample) |
| WO (1) | WO2015165966A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106535924A (zh) | 2014-04-29 | 2017-03-22 | 阿费里斯股份公司 | 阿尔茨海默病(ad)的治疗和预防 |
| KR102506460B1 (ko) * | 2014-04-29 | 2023-03-03 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병（ａｄ）의 치료 및 예방 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994016327A1 (en) * | 1993-01-14 | 1994-07-21 | Pollard Harvey B | Methods and compositions for blocking amyloid protein ion channels |
| EP1007040B1 (en) * | 1997-08-21 | 2002-05-08 | P.N. Gerolymatos S.A. | Use of phanquinone for the treatment of alzheimer's disease |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| CN104436212A (zh) * | 2010-03-29 | 2015-03-25 | 诺华股份有限公司 | 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物 |
| CN106535924A (zh) * | 2014-04-29 | 2017-03-22 | 阿费里斯股份公司 | 阿尔茨海默病(ad)的治疗和预防 |
| KR102506460B1 (ko) * | 2014-04-29 | 2023-03-03 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병（ａｄ）의 치료 및 예방 |
-
2015
- 2015-04-29 WO PCT/EP2015/059339 patent/WO2015165966A1/en not_active Ceased
- 2015-04-29 PT PT157200593T patent/PT3137093T/pt unknown
- 2015-04-29 AU AU2015254663A patent/AU2015254663B2/en active Active
- 2015-04-29 DK DK15720059.3T patent/DK3137093T3/en active
- 2015-04-29 HU HUE15720059A patent/HUE037501T2/hu unknown
- 2015-04-29 US US15/307,082 patent/US10478454B2/en active Active
- 2015-04-29 SI SI201530145T patent/SI3137093T1/en unknown
- 2015-04-29 ES ES17189527T patent/ES2824763T3/es active Active
- 2015-04-29 EP EP17189527.9A patent/EP3269376B1/en active Active
- 2015-04-29 LT LTEP15720059.3T patent/LT3137093T/lt unknown
- 2015-04-29 ES ES15720059.3T patent/ES2651537T3/es active Active
- 2015-04-29 CA CA2946928A patent/CA2946928C/en active Active
- 2015-04-29 NO NO15720059A patent/NO3137093T3/no unknown
- 2015-04-29 EP EP15720059.3A patent/EP3137093B1/en active Active
- 2015-04-29 KR KR1020167033332A patent/KR102388363B1/ko active Active
- 2015-04-29 JP JP2016565267A patent/JP6692755B2/ja active Active
- 2015-04-29 CN CN201580029861.5A patent/CN106659738B/zh active Active
- 2015-04-29 HR HRP20171896TT patent/HRP20171896T1/hr unknown
- 2015-04-29 PL PL15720059T patent/PL3137093T3/pl unknown
-
2017
- 2017-12-13 CY CY20171101303T patent/CY1119674T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3269376A1 (en) | 2018-01-17 |
| ES2824763T3 (es) | 2021-05-13 |
| AU2015254663A1 (en) | 2016-11-10 |
| CN106659738B (zh) | 2021-02-09 |
| HRP20171896T1 (hr) | 2018-02-23 |
| PL3137093T3 (pl) | 2018-06-29 |
| CA2946928A1 (en) | 2015-11-05 |
| KR20160145822A (ko) | 2016-12-20 |
| ES2651537T3 (es) | 2018-01-29 |
| KR102388363B1 (ko) | 2022-04-19 |
| DK3137093T3 (en) | 2017-12-11 |
| AU2015254663B2 (en) | 2020-04-02 |
| CN106659738A (zh) | 2017-05-10 |
| SI3137093T1 (en) | 2018-01-31 |
| PT3137093T (pt) | 2017-12-19 |
| EP3137093B1 (en) | 2017-09-13 |
| HUE037501T2 (hu) | 2018-08-28 |
| EP3137093A1 (en) | 2017-03-08 |
| JP2017518275A (ja) | 2017-07-06 |
| JP6692755B2 (ja) | 2020-05-13 |
| CA2946928C (en) | 2023-01-31 |
| LT3137093T (lt) | 2017-12-11 |
| WO2015165966A1 (en) | 2015-11-05 |
| EP3269376B1 (en) | 2020-07-15 |
| NO3137093T3 (enExample) | 2018-02-10 |
| US20170049812A1 (en) | 2017-02-23 |
| US10478454B2 (en) | 2019-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125136T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CY1124013T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CY1122344T1 (el) | Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων | |
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| CY1122148T1 (el) | Συνθεσεις που περιεχουν βακτηριακα στελεχη | |
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| CY1120373T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| MA45192A (fr) | Traitement d'association | |
| HUE052095T2 (hu) | Keratin kezelési készítmények és eljárások | |
| MX386234B (es) | Vacuna para la malaria. | |
| PT3481846T (pt) | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda | |
| MX2017004473A (es) | Formulaciones de betalactamasa y usos de las mismas. | |
| MX380252B (es) | Crenezumab para usarse en el tratamiento de enfermedad de alzheimer. | |
| WO2019173795A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| CY1122784T1 (el) | Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1 | |
| MX392976B (es) | Composiciones que comprenden cepas bacterianas. | |
| MX2022013283A (es) | Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales. | |
| CY1125031T1 (el) | Μεθοδος για γενετικη θεραπεια χρησιμοποιωντας τον ιο aav-xbp1s/gfp και χρηση αυτης στην προληψη και τη θεραπεια της αμυοτροφικης πλευρικης σκληρυνσης | |
| PT3413870T (pt) | Igmesina para utilização no tratamento de doença de alzheimer | |
| LT3458045T (lt) | Ebselenas, skirtas naudoti menjero ligos gydymui | |
| WO2015165980A3 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| EP3137097C0 (en) | TREATMENT AND PREVENTION OF ALZHEIMER | |
| CY1119674T1 (el) | Θεραπεια και προληψη της νοσου αλτσχαϊμερ (ad) | |
| HUE066487T2 (hu) | Regorafenib és nivolumab kombinációja rák kezelésére |